U.S. flag

An official website of the United States government

NM_000263.4(NAGLU):c.2116C>T (p.Gln706Ter) AND NAGLU-related disorder

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Aug 17, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003403552.4

Allele description [Variation Report for NM_000263.4(NAGLU):c.2116C>T (p.Gln706Ter)]

NM_000263.4(NAGLU):c.2116C>T (p.Gln706Ter)

Gene:
NAGLU:N-acetyl-alpha-glucosaminidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q21.2
Genomic location:
Preferred name:
NM_000263.4(NAGLU):c.2116C>T (p.Gln706Ter)
HGVS:
  • NC_000017.11:g.42544122C>T
  • NG_011552.1:g.13190C>T
  • NM_000263.4:c.2116C>TMANE SELECT
  • NP_000254.2:p.Gln706Ter
  • NC_000017.10:g.40696140C>T
  • NM_000263.3:c.2116C>T
Protein change:
Q706*
Links:
dbSNP: rs752527478
NCBI 1000 Genomes Browser:
rs752527478
Molecular consequence:
  • NM_000263.4:c.2116C>T - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
NAGLU-related disorder
Synonyms:
NAGLU-related condition
Identifiers:

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV004104201PreventionGenetics, part of Exact Sciences
criteria provided, single submitter

(ACMG Guidelines, 2015)		Likely pathogenic
(Aug 17, 2023) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From PreventionGenetics, part of Exact Sciences, SCV004104201.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

The NAGLU c.2116C>T variant is predicted to result in premature protein termination (p.Gln706*). This variant was reported in homozygous and compound heterozygous state an individuals with Sanfilippo syndrome B, also known as Mucopolysaccharidosis IIIB (Zhao et al. 1998. PubMed ID: 9443875; Whitley et al. 2018. PubMed ID: 29661560). This variant occurs within the last exon and is not predicted to result in nonsense mediated decay, however pathogenic variants upstream and downstream have been reported. This variant is reported in 0.0015% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/17-40696140-C-T). This variant is interpreted as likely pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024